Lawrence and Isabel Barnett Drug Development Program
Supports teams evaluating novel or repurposed ALS therapies through preclinical studies that prepare candidates for later patient testing.
The Lawrence and Isabel Barnett Drug Development Program supports the preclinical assessment of novel therapies or repositioned treatment approaches in preparation for clinical testing of ALS treatments. The program is currently between cycles as of 2026-05-27 — the program page indicates it is not accepting applications and no 2026 RFA PDF is published. The most recent published cycle on the funder's site is 2023, suggesting an approximately annual cadence.
Max award—
Realistic median—
Success rate—
Decision time—
No upcoming rounds verified. Cadence: Annual.